Inside Valeant Pharmaceuticals' Bid for Allergan

Here’s why this pharmaceutical megamerger seems like a good deal for both companies.

Apr 24, 2014 at 6:30PM

Earlier this week, Valeant Pharmaceutical (NYSE:VRX) made a public offer to buy rival Allergan (NYSE:AGN). Let's review the major questions this huge potential deal raises, to see whether it's a smart move – and whether or not it'll actually happen.

What is Allergan?
Allergan sells specialty pharmaceuticals and medical devices, with businesses spanning eye care, dermatology and aesthetics. It's best-known for its Botox franchise, but its largest business segment is eye health, with treatments for dry eyes, glaucoma, inflammation, allergies, and retinal diseases.

In 2013, Allergan's sales grew 11%;  the company generated 31% operating margins ; 38%  of sales came from outside the United States; and it spent $1 billion (more than 15% of sales ) on research and development.

Why does Valeant want to buy it?
Valeant and Allergan are focused on similar therapeutic areas: eye care and dermatology. Together, the combined companies would be the second-largest  global player in eye health, with a cheaper, more effective combined sales force to boot.

According to Valeant's estimates, Allergan gets 60%  of its revenue from durable products – those that don't rely on patent protections to generate sales – and 65% from products with limited reimbursement risk from government-run health-care programs. Obviously, these types of products are attractive because they'll generate sales over a long period. Governments spend a lot on health care, but they aren't the best customers. They have a tendency to demand huge discounts, pay late, and introduce numerous bureaucratic hassles.

Furthermore, Valeant believes that it can trim a lot of fat from Allergan's cost structure, achieving $2.7 billion in cost synergies by cutting $1.8 billion in overhead costs and $900 million in research and development costs from the combined companies.

How much did Valeant offer?
Valeant is offering $48.30 in cash and 0.83 shares of Valeant for each outstanding share of Allergan. Based on Allergan's diluted share count of 307 million , the deal is worth approximately $49 billion. To finance the cash portion of the deal, Valeant has secured $15.5 billion in debt financing, which is expected to have an interest rate of 5.5%.  

Is it a good deal for Valeant shareholders?
On paper, this looks like a great deal. If the combined company achieves its targeted synergies, shareholders will benefit as the company's per-share cash earning power rises between 25% and 30%.  In other words, the benefit of folding Allergan's business into Valeant will more than offset any dilution for current shareholders. The deal will also shore up Valeant's balance sheet and reduce leverage.

Valeant CEO J. Michael Pearson has an outstanding track record of making smart purchases and delivering target synergies. But Valeant has never done a deal of this size ever before. Inevitably, there will be hiccups, and only time will tell whether Pearson's making a wise move here.

Will the deal go through?
Prior to making this offer, Valeant hired two law firms for advice -- Skadden, Arps, Slate, Meagher & Flom LLP, and Osler, Hoskin & Harcourt LLP . If these lawyers aren't the best in the world, they're at least among the most prestigious and expensive. Since both firms concluded that there shouldn't be any antitrust concerns, I suspect regulators will approve the deal.

Will shareholders also say yes? I think they likely will. Allergan insiders, who have the greatest incentive to reject the deal, only own 0.18% of shares. By contrast, Allergan's largest shareholder, the Bill Ackman-led Pershing Square, vocally favors the deal. Ackman is so enthused by the deal (and Valeant) that he has agreed to accept 100% stock for his ownership stake. 

Of course, I do expect some saber-rattling by Allergan's board of directors. They'll hire an investment bank to look for competing offers, but I don't think any better ones will come. Allergan's board could make a perfunctory effort to haggle with Valeant for a better price, but in the end, I think this deal will get done at or near Valeant's initial offer price.

Foolish bottom line
The price Valeant would pay looks reasonable in light of potential synergies, and shareholders should benefit. But integrating the two companies could prove challenging over the next several years, and investors in either company should keep a careful eye out for any signs of trouble.

Invest in the next wave of health care innovation
The Economist compares this disruptive invention to the steam engine and the printing press. Business Insider says it's "the next trillion dollar industry." And the technology  behind is poised to set off one of the most remarkable health care revolutions in decades. The Motley Fool's exclusive research presentation dives into this technology's true potential, and it's ability to make life-changing medical solutions never thought possible.  To learn how you can invest in this unbelievable new technology, click here now to see our free report.

Brendan Mathews owns shares of Valeant Pharmaceuticals. The Motley Fool recommends Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.


Compare Brokers